NEW YORK, Nov. 19, 2021 /PRNewswire/ -- According to the report "Global Osteoporosis Drugs Market 2019-2023", North America accounted for the highest market share in 2018. Factors such as growing incidence and prevalence of osteoporosis, strong presence of major vendors, and increased patient access to reimbursement schemes are creating significant growth opportunities for the market.
View Free Sample to know additional highlights and key points on various market segments and their impact in coming years.
The global osteoporosis drugs market size is expected to grow by USD 1.85 billion from 2018 to 2023 at a CAGR of nearly 5%.
Amgen Astellas BioPharma K.K., Amgen Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Cipla Inc., DAIICHI SANKYO COMPANY LIMITED, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Mylan N.V., Novartis AG, Noven Pharmaceuticals, Inc., Pfizer Inc., Radius Health, Inc., Taisho Pharmaceutical Holdings Co., Ltd.,Teva Pharmaceutical Industries Ltd., UCB S.A., Upsher-Smith Laboratories, LLC., Zydus Cadila are some of the vendors in the market.
The osteoporosis drugs market is moderately fragmented.
Some prominent vendors are entering into strategic alliances to develop drugs for the treatment of osteoporosis.
Vendors are also launching new drugs such as anabolic drugs for the treatment of osteoporosis and expanding their biomanufacturing plants to increase their geographical reach.
To understand more about additional vendors with various other strategies and their product offerings, Read Sample Report.
Geographical Market Analysis
North America accounted for the highest market share in 2018.
The market's growth in this region will be slower than the growth of the market in Asia, Europe, and ROW.
However, the region will account for the largest market share during the forecast period.
The US is a key country for the osteoporosis drugs market in North America.
To know more about this market's geographical distribution, Download Our Free Sample
Key Market Trends:
Increase in strategic alliances is one of the key trends in the market.
In July 2017, Radius Health, Inc. announced that it had entered into a license and development agreement with Teijin Limited in Japan for abaloparatide-SC.
In February 2018, Radius Health, Inc. entered into a scale-up and commercial supply agreement with 3M. According to the agreement, 3M will exclusively manufacture Phase III and global commercial supplies of abaloparatide-patch.
In August 2018, Health Decisions, Inc and Comac Medical announced the expansion of a strategic alliance to conduct women's health clinical trials in the US and Europe.
Key Market Challenges:
High genericization and patent expiry is one of the challenges impeding the market.
Currently, the global osteoporosis drugs market is dominated by generics due to the patent expiries of branded drugs.
The cost of generic drugs/biosimilars is less than that of branded ones.
View Free Sample to uncover more facts for market trends and challenges impacting the osteoporosis drugs market.
Customize Your Report
Don't miss out on the opportunity to speak to our analysts and know more insights about this market forecast report. Our analysts can also help personalize this report according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
We offer USD 1000 worth of FREE customization at the time of purchase. Speak to our Analyst now!
Vitamin D3 Market: The vitamin D3 market has been segmented by application (functional nutrition, pharmaceutical, and others) and geography (North America, Europe, Asia, and ROW). Download Free Sample Report
Protein Supplements Market: The protein supplements market has been segmented by distribution channel (retail outlets and online stores) and geography (North America, Europe, APAC, South America, and MEA). Download Free Sample Report
Osteoporosis Drugs Market Scope
Growth momentum & CAGR
Accelerate at a CAGR of nearly 5%
Market growth 2021-2025
USD 1.85 billion
YoY growth (%)
Asia, Europe, North America, and ROW
Performing market contribution
North America at 44%
Leading companies, competitive strategies, consumer engagement scope
Amgen Astellas BioPharma K.K., Amgen Inc., Asahi Kasei Corporation, Astellas Pharma Inc., Cipla Inc., DAIICHI SANKYO COMPANY LIMITED, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Mylan N.V., Novartis AG, Noven Pharmaceuticals, Inc., Pfizer Inc., Radius Health, Inc., Taisho Pharmaceutical Holdings Co., Ltd.,Teva Pharmaceutical Industries Ltd., UCB S.A., Upsher-Smith Laboratories, LLC., Zydus Cadila
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, future consumer dynamics, market condition analysis for forecast period.
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
View original content to download multimedia:https://www.prnewswire.com/news-releases/osteoporosis-drugs-market-size-to-increase-by---usd-1-85-bn-technavios-research-insights-highlight-new-drug-approvals-and-favorable-pipeline-as-key-driver-301428051.html